Organic Sythesis

有机合成

• 批准号: 8933536
• 负责人: Ouathek Ouerfelli
• 金额: $ 32.13万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8933536
• 关键词: Androgen Receptor; Biological Availability; Biology; Cancer Center Support Grant; Cancer Detection; Chemicals; Chemistry; Commit; Communities; Core Facility; Development; Evaluation; Grant; Human Resources; Instruction; Laboratories; Legal patent; Licensing; Malignant neoplasm of prostate; Medical; Medicine; Memorial Sloan-Kettering Cancer Center; Methodology; Methods; Mission; Organic Synthesis; Paper; Pharmaceutical Preparations; Phase; Prevention; Procedures; Process; Property; Prostate Cancer therapy; Publications; Research; Research Personnel; Research Support; Resistance; Services; Therapeutic Agents; Time; Work; cancer therapy; chemical synthesis; novel; preclinical study; programs; research and development; tool

The mission of the Organic Synthesis Core Facility (OSCF) is to provide chemical synthesis services to the MSKCC community, and to maintain a state-of-the art facility with expert professional personnel in chemical synthesis. This Chemistry Core Facility operates at the interface of chemistry, biology and medicine, and has the capability to support medical chemistry efforts to evolve neg agents in support of MSKCC investigators. The work of the Core has greatly facilitated preclinical studies at the Center. The Core synthesizes novel molecules that are not readily available, by either following described procedures or by developing new and more suitable methods of synthesis. MSKCC is committed to the research and development of new tools and therapeutic agents for cancer detection, prevention, and treatment. The specialized services provided by the Organic Synthesis Core have supported the research of 16 investigators in the past year. During the past grant period the work of the Core has contributed to 60 publications of researchers from 5 research programs. For example, the Sawyers laboratory used the Core's services to develop a new androgen receptor antagonist as a potential therapy for prostate cancer. In a relatively short time, the Core was able to invent a new chemical process to synthesize an antagonist that was safe, scalable, and reproducible. Most importantly, controls of delivered batches made it easy to adjust the methodology when batch bioavailability assessments varied significantly. This has so far resulted in two licensed patents, a high profile paper, and most importantly a drug with desirable properties, now known as ARN-509, that will shortly enter Phase III evaluation in castrate resistant prostate cancer.

有机合成核心设施（OSCF）的任务是为 MSKCC社区，并维护最先进的设施 合成。该化学核心设施在化学，生物学和医学的界面上运作，并具有 支持医学化学努力的能力，以进化为支持MSKCC调查人员的否定代理。 核心的工作极大地促进了该中心的临床前研究。核心综合新颖 通过以下描述程序或开发新的和 合成的更合适的方法。 MSKCC致力于研究新工具的研究和开发 以及用于癌症检测，预防和治疗的治疗剂。提供的专业服务 在过去的一年中，有机合成核心支持了16位研究者的研究。在过去 授予期核心的工作为来自5项研究的60名研究人员贡献了 程序。例如，锯生实验室使用核心的服务来开发新的雄激素 受体拮抗剂是前列腺癌的潜在疗法。在相对较短的时间内，核心能够 发明一种新的化学过程，以合成安全，可扩展且可再现的拮抗剂。最多 重要的是，交付批量的控制使得批量生物利用度时可以轻松调整方法 评估差异很大。到目前为止，这已经获得了两项许可的专利，一份备受瞩目的纸张，以及 最重要的是具有理想特性的药物，现在称为ARN-509，它将很快进入III期 castrate抗性前列腺癌的评估。